Health care stocks climbed late Monday afternoon with the NYSE Health Care Index up 0.5% and the Health Care Select Sector SPDR Fund (XLV) rising 0.8%.
The iShares Biotechnology ETF (IBB) climbed 1.3%.
In corporate news, Unity Biotechnology (UBX) shares fell 28%. The company's UBX1325, the diabetic macular edema treatment for patients with poor vision, didn't achieve statistical non-inferiority at the primary analysis endpoint in a phase 2b trial.
TransCode Therapeutics (RNAZ) shares dropped 38%. The company agreed to sell shares to raise $10 million.
23andMe (ME) filed for Chapter 11 bankruptcy protection to help facilitate a potential sale, while Anne Wojcicki resigned as chief executive officer, less than a month after she attempted to buy the genetic testing firm. 23andMe shares tumbled 59%.
Novo Nordisk (NVO) secured exclusive global rights to United Laboratories International's therapeutic candidate for obesity and type 2 diabetes in a licensing deal worth up to $2 billion. Novo shares shed 2%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.